Semaglutide Reconstitution Calculator

The calculator's "Doses per vial" assumes a set duration of activity, but Semaglutide is designed for sustained action. Natural human GLP-1 is degraded in minutes, yet Semaglutide incorporates two key modifications: an α-aminoisobutyric acid (Aib) at position 8 that prevents DPP‑4 degradation, and a C18 fatty-diacid side chain linked to Lys26 that promotes reversible albumin binding, resulting in a plasma half‑life of approximately 160 hours (6–7 days). This extended half-life is crucial because it allows once-weekly subcutaneous injections. If a researcher uses the calculator to prepare a daily dosing schedule, they would be administering far more total peptide than necessary. The calculator's "Doses per vial" count is a static number; for Semaglutide, you must manually account for the once-weekly frequency.

The calculator's default assumption of solubility can be problematic. Scientific solubility data indicates that semaglutide is insoluble in water at neutral pH (less than 0.1 mg/mL), with complete dissolution often requiring an acidic environment (for example, at pH 1.0, solubility can be 1.25 mg/mL after adjusting with HCl). Because commercial pharmaceutical formulations contain proprietary stabilisers, there is no universal rule, but researchers have reported that commercial 1 mg and 2 mg vials reconstitute clearly with 2 mL of BAC water. If you encounter a clumpy powder that does not fully dissolve, it is a physical indicator that the calculated concentration is impossible to achieve in water alone. The safest approach is to follow the exact diluent volume recommended by your supplier, even if the calculator marks a smaller volume as "Best," as using insufficient water could compromise the solubility and stability of the entire vial.

The calculator's "Doses per vial" count is a pure mathematical maximum, but the physics of the peptide's stability is different. Once reconstituted, semaglutide solution should be stored at 2‑8 °C (refrigerator temperature) and is typically stable for approximately 28 days under proper refrigeration. For the branded injectable pen, which does not require reconstitution, the solution is stable at room temperature for 28 days once opened. For a researcher who reconstitutes a 5 mg vial and uses a once‑weekly dose of 0.5 mg, the "Doses per vial" would be about 10 weeks' worth, but the 28‑day window would expire long before the vial is empty. Therefore, a single vial cannot be used for more than 4 weeks, regardless of how much peptide remains, unless you aliquot and freeze the solution immediately after mixing.

The calculator will show one number for a given dose, but for Semaglutide, the dose is not static. The FDA‑approved titration protocol for subcutaneous semaglutide begins with 0.25 mg once weekly for four weeks, followed by stepwise increases at four‑week intervals to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. If you reconstitute a 5 mg vial, the calculator can help at each step, but the "Doses per vial" count will shrink as the dose increases. A single 5 mg vial reconstituted with a fixed volume of BAC water could provide the first few weeks of the titration, but you will need to plan to reconstitute additional vials for the higher‑dose weeks. The calculator does not automatically account for this dynamic schedule; you must manually recalculate at each dose step.

The calculator's output is purely a matter of mass and volume. However, clinical trial data report nausea in up to 44% of participants and vomiting in 24%, which are more frequent during the first 4‑5 weeks after starting treatment and after each dose increase. To reduce side effects, the standard approach is to follow the slow titration schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each for 4 weeks). The calculator does not include this clinical protocol. If you attempt to bypass the initial low doses, the nausea and vomiting can be severe enough to force discontinuation of the research. The volume drawn by the calculator is not a tool to manage side effects; the side effects depend on the total mass and the body's adaptation to the GLP‑1 mechanism, not the injection volume.